Form 4: Xenon CFO Kelly Granted 255,000 Equity Awards

Xenon Pharmaceuticals Inc. Chief Financial Officer Thomas Patrick Kelly was granted 225,000 share options and 30,000 restricted share units on October 15, 2025.

Summary

• Thomas Patrick Kelly, Chief Financial Officer of Xenon Pharmaceuticals Inc. (XENE), was granted equity awards on October 15, 2025.
• The awards include 225,000 share options with an exercise price of $41.90, expiring on October 14, 2035.
• These share options vest 25% on October 15, 2026, with the remaining 75% vesting monthly over the subsequent three years.
• Additionally, 30,000 restricted share units (RSUs) were granted, each representing a contingent right to receive one Common Share.
• The RSUs vest 25% on each of the first four anniversaries of the grant date, commencing October 15, 2026.
• Following these transactions, Kelly beneficially owns 225,000 share options and 30,000 restricted share units.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is generally a positive signal, as it aligns management's interests with shareholders and incentivizes long-term performance. It reflects a commitment to executive retention and future value creation, though it's a routine compensation event rather than a groundbreaking development.

Positives

• The equity grants align the Chief Financial Officer's long-term interests with those of shareholders, incentivizing company performance.
• The significant number of awards (255,000 total) demonstrates a commitment to retaining key executive talent.
• The vesting schedules encourage sustained performance over several years.

Negatives

• These are grants of future equity, not immediate cash compensation or stock ownership, meaning no immediate liquidity for the executive.
• The value of the awards is contingent on the future stock price performance of Xenon Pharmaceuticals Inc.

Risks

• The value of the share options and restricted share units is subject to the market price fluctuations of Xenon Pharmaceuticals Inc. common shares.
• Vesting conditions require continued employment and may be subject to performance criteria not detailed in this filing.
• Future share issuance upon the exercise of options and conversion of RSUs could lead to minor dilution for existing shareholders.

Future Outlook

These equity grants are designed to incentivize the Chief Financial Officer to contribute to the long-term growth and success of Xenon Pharmaceuticals Inc., aligning executive performance with shareholder value creation over the vesting periods.

Industry Context

Granting equity awards such as stock options and restricted share units is a standard and widely adopted practice in the biotechnology and pharmaceutical industries for executive compensation. This approach aims to attract, retain, and motivate key personnel by linking their compensation directly to the company's long-term performance and shareholder value.

Comparison to Industry Standards

• Equity compensation, including stock options and restricted share units, is a common component of executive pay packages across the biotech and pharmaceutical sectors, similar to practices at companies like Biogen Inc. or Amgen Inc.
• The vesting schedules, typically over three to four years, are consistent with industry norms designed to promote long-term retention and performance.
• The specific size of the grant (255,000 total awards) would need to be benchmarked against peer companies of similar market capitalization and stage of development to assess if it is within typical ranges for a CFO role.

Stakeholder Impact

• Shareholders: Potentially positive, as executive compensation is aligned with long-term company performance, which could lead to increased shareholder value. However, future share issuance upon vesting/exercise could lead to minor dilution.
• Employees: May signal stability and a commitment to executive retention, potentially boosting morale.
• Management (Thomas Patrick Kelly): Significant incentive for long-term performance and retention, with potential for substantial personal wealth creation tied to company success.

Next Steps

• Continued vesting of the granted share options and restricted share units according to their respective schedules.
• Potential exercise of share options by Thomas Patrick Kelly upon vesting and favorable stock price movement.
• Conversion of restricted share units into common shares upon vesting.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Insider Transaction, Equity Grant, Stock Options, Restricted Share Units, Executive Compensation, Thomas Patrick Kelly, CFO, Form 4